GBP Health / Biotech News 05-11-2010:
Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. See www.gbpcap.com. The digest is published two to four days a week. If you have colleagues who would be interested in receiving this digest by email, they can be added to the list at: http://www.gbpcap.com/. Also, the complete history of the entire content of all news articles in our digests since August, 2005 is searchable with Google's enterprise search engine at the same site.
EurekAlert - Biology:
Public Release: 11-May-2010
Cell Death & Disease
Cancer: Trapping the escape artist
Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.
Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Public Release: 11-May-2010
Researchers share insights into RNA
Investigators from around the country came to Sanford-Burnham Medical Research Institute on Friday, May 7, to share their knowledge of the burgeoning young field of microRNAs. These small non-coding nucleic acids turn off proteins and have been implicated in viral infection, cancer, cardiovascular disease, HIV and numerous other conditions.
Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Public Release: 11-May-2010Cancer Cell
Scientists design new drug type to kill lymphoma cells
A new type of drug designed to kill non-Hodgkin's lymphoma tumor cells could lead to potential nontoxic therapies for cancer patients.
Contact: Jenny Song
jsong@waxmancancer.org
212-348-0136
Samuel Waxman Cancer Research Foundation
Public Release: 10-May-2010Journal of Cell Biology
Mutations that cause Parkinson's disease prevent cells from destroying defective mitochondria
Mutations that cause Parkinson's disease prevent cells from destroying defective mitochondria, according to a study published online May 10 in the Journal of Cell Biology.
Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Public Release: 10-May-2010Nature Biotechnology
Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms
The availability of more affordable drugs, vaccines and diagnostics that would help countless people worldwide is the foremost benefit expected from a growing number of collaborations between biotech firms in developing countries, according to a study to be published Monday, May 12, in the UK journal Nature Biotechnology.
Genome Canada, Ontario Genomics Institute, International Development Research Center
Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
McLaughlin-Rotman Centre for Global Health\
Source - Science Daily Science Daily :
Please note : Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary , rather than the article title.
Parkinson's Disease Treatments Associated With Compulsive Behaviors
May 11, 2010 — Pathological gambling, compulsive shopping, binge eating and other impulse control disorders appear to be more common among individuals taking dopamine agonist medications for Parkinson's disease, ...
http://www.sciencedaily.com/releases/2010/05/100510161256.htm
MicroRNA Dysregulation May Contribute to Melanoma Development
May 11, 2010 — Researchers in Canada have identified differential expression of miRNAs as a contributing factor in melanoma ...
http://www.sciencedaily.com/releases/2010/05/100510141427.htm
How Cancer Cells Loose Their (Circadian) Rhythm
May 11, 2010 — Unlike the current assumption that cancer cells divide uncontrollably because their Circadian clocks are broken, the new study finds that cell division is uncontrolled in an immortal cell line with ...
http://www.sciencedaily.com/releases/2010/05/100510151344.htm
Vital Functions Monitored With Wearable and Implantable Devices
May 11, 2010 — Physiological signals can nowadays be easily monitored with measurement devices implanted inside a living body. A Finnish researcher believes that the next tech-savvy generation represents a ...
http://www.sciencedaily.com/releases/2010/05/100510105031.htm
Medical Costs of Cancer Have Nearly Doubled Over the Past Two Decades
May 11, 2010 — A new analysis finds that the costs of treating cancer have nearly doubled over the past two decades and that the shares of these costs that are paid for by private health insurance and Medicaid have ...
http://www.sciencedaily.com/releases/2010/05/100510075035.htm
May 11, 2010 — More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia to 71 percent three years after diagnosis, according to new ...
http://www.sciencedaily.com/releases/2010/05/100510105023.htm
Angiogenesis Inhibitors Are Safe Cancer Drugs Despite Hypertension Risk, Panel Concludes
May 11, 2010 — A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has ...
http://www.sciencedaily.com/releases/2010/05/100511111927.htm
New Method for Developing Safer Drugs
May 10, 2010 — Amodiaquine was introduced as an antimalarial drug, but was withdrawn when serious adverse effects were observed. Scientists in Sweden have now developed a method that can be used to develop safer ...
http://www.sciencedaily.com/releases/2010/05/100509202645.htm
Drug Now Used to Treat Erectile Dysfuncton May Enhance Delivery of Herceptin to Certain Brain Tumors
May 10, 2010 — New research suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug herceptin to certain hard-to-treat brain tumors. The ...
http://www.sciencedaily.com/releases/2010/05/100507175257.htm
Novel Artificial Pancreas Successfully Controls Blood Sugar More Than 24 Hours
May 10, 2010 — An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of ...
http://www.sciencedaily.com/releases/2010/04/100414152127.htm
New Way to 'Rescue' Treatment Sensitivity of Breast Cancer Cells
May 10, 2010 — Researchers have identified a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor-positive breast ...
http://www.sciencedaily.com/releases/2010/05/100510092006.htm
New Treatment Method Possible in Cardiac Surgery
May 9, 2010 — A clinical trial conducted in Sweden has found that an element in human blood, fibrinogen, is likely more vital to the blood’s clotting ability in connection with heart surgery than previously ...
http://www.sciencedaily.com/releases/2010/05/100509202643.htm
Source - Health Day:
Health Highlights: May 11, 2010
- FDA Alerting Professionals to Misleading Drug Ads
- Michelle Obama Endorses Weight Guidelines for Moms-to-Be
- Toxins in Children's Jewelry Targeted
- New Rules Developed for Chicken, Turkey Safety
- Researchers Study Ultrasound Contraceptive for Men
Parkinson's Drugs Tied to Compulsive Behaviors
Impulse control disorders noted in patients include gambling and binge eating
Clinical Trials Update: May 11, 2010
- Asthma
- Crohn's Disease
- Fibromyalgia
Source - Yahoo Biotech News:
Alnylam Scientists and Collaborators Publish Research on Key Mechanism for Delivery of RNAi Therapeutics with Lipid Nanoparticles (LNPs)- Business Wire - Tue 10:56 am ET
CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles .
Abbott in new deal to target emerging markets- AP - 1 hour, 58 minutes ago
Abbott Laboratories will license at least 24 products in emerging markets through a new unit created to boost sales outside of the U.S., the drug and medical device maker said Tuesday.
Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy for Growth in Emerging Markets- Business Wire - Tue 11:13 am ET
WHITEHOUSE STATION, N.J.----Merck & Co., Inc. today hosted its first R&D and Business Briefing since completion of the Merck and Schering-Plough merger and outlined the company's strategy to drive global business growth.
Source - Google Health News:
Gene Therapy Center at University of North Carolina Utilizes Unotron ...
Earthtimes (press release)
DALLAS - (Business Wire) The Gene Therapy Center at the University of North Carolina (UNC) asserts that Unotron's ruggedly designed, airtight SpillSeal® ...
UH-led team refines gene therapy
Honolulu Star-Bulletin
Dr. Stefan Moisyadi said his method, offering potential for gene therapy trials, "eliminates toxic effects. It's really working well. ...
Source - Medical News Today:
New Findings Complicate Use Of Stem Cells
A hitherto unknown function that regulates how stem cells produce different types of cells in different parts of the nervous system has been discovered by researchers at Linköping University. The results improve our understanding of how stem cells work which is crucial for our ability to use stem cells to treat and repair organs. Stefan Thor, professor of Developmental Biology, and graduate students Daniel Karlsson and Magnus Baumgardt are now publishing the findings of their research in the prestigious scientific journal PLoS Biology.
http://www.medicalnewstoday.com/articles/188259.php
Agents That Keep Insulin Working Longer Developed By Mayo-Led Research Team
More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that. The researchers say their findings, published in the May issue of PLoS ONE, could lay the foundation for a new class of drugs for treating diabetes. The tiny molecules they developed work by inhibiting a powerful molecular machine known as insulin-degrading enzyme (IDE) from chewing up the insulin hormone. That keeps insulin in the body longer to help remove glucose (simple food sugar) from the blood.
http://www.medicalnewstoday.com/articles/188191.php
When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer . The "Suntelligence: How Sun Smart is Your City?" online survey polled more than 7,000 adults nationwide to determine their knowledge, attitudes and behaviors toward tanning, sun protection and skin cancer detection. Twenty-six cities were ranked based on respondents' answers to several questions in each category.
http://www.medicalnewstoday.com/articles/188198.php
Source - MIT's Technology Review:
Patient's Social Network Predicts Drug Outcomes
http://www.technologyreview.com/biomedicine/25276/?a=f
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.